Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

BACKGROUND: Although the dual anti-HER2 therapy, namely, pertuzumab plus trastuzumab and docetaxel, has shown promising results in HER2+ breast cancer patients, whether the dose, efficacy and safety of this treatment differs from those of other pertuzumab-based dual anti-HER2 therapies remain contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shanshan, Liang, Yu, Feng, Zhangying, Wang, Mingxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805346/
https://www.ncbi.nlm.nih.gov/pubmed/31638935
http://dx.doi.org/10.1186/s12885-019-6132-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805346/
https://www.ncbi.nlm.nih.gov/pubmed/31638935
http://dx.doi.org/10.1186/s12885-019-6132-0

Ejemplares similares